menu
    • menu

    Company profile for Teikoku Pharma USA

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology. Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and Versatis® brands. To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries. TPU recen...
    Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology. Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and Versatis® brands. To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries. TPU recently also received NDA approval for Non-alcohol Docetaxel injection currently available in the US.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Teikoku Pharma USAUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1718 Ringwood Ave San Jose, CA 95131
    Telephone
    Telephone
    (408) 501-1800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://teikokuusa.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teikoku Announces Lidoderm® Approval In China
    Teikoku Announces Lidoderm® Approval In China

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/teikoku-pharma-usa-inc-announces-nmpa-approved-lidoderm-in-china-on-may-8-2024-302159080.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Teikoku Pharma bags FDA fast track for post-surgical transdermal analgesic
    Teikoku Pharma bags FDA fast track for post-surgical transdermal analgesic

    21 Jun 2023

    // Robert Barrie PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/teikoku-pharma-bags-fda-fast-track-for-post-surgical-transdermal-analgesic/

    Robert Barrie PHARMACEUTICAL TECHNOLOGY
    21 Jun 2023
    Share Share
    Teikoku Pharma granted FDA Fast Track Designation for TPU-006
    Teikoku Pharma granted FDA Fast Track Designation for TPU-006

    21 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/teikoku-pharma-granted-fda-fast-track-designation-for-tpu-006-a-novel-4-day-dexmedetomidine-transdermal-system-for-post-operative-pain-management-301856234.html

    PR NEWSWIRE
    21 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search